# Doxorubicin

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

ATC codes: L01DB01

| | |
|---|---|
| **Indication** | Follicular lymphoma ICD11 code: 2A80.Z |
| **INN** | Doxorubicin |
| **Medicine type** | Chemical agent |
| **List type** | Complementary |
| **Formulations** | **Parenteral > General injections > IV:** 10 mg in vial (hydrochloride) powder for injection ; 50 mg in vial (hydrochloride) powder for injection ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride) |
| **EML status history** | First added in 2015 (TRS 994)<br>Changed in 2023 (TRS 1049) |
| **Sex** | All |
| **Age** | Adolescents and adults |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Tags** | Cancer |
| **Wikipedia** | Doxorubicin |
| **DrugBank** | Doxorubicin |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.